chufangao/CTO huggingface dataset:
Clinical trial NCT03818776: Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
Official title: A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D)
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Safety
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-30
Primary completion date: 2022-01-27
Completion date: 2022-01-27
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
IPD time frame: Beginning 3 months and ending 5 years following article publication
IPD access criteria: Will be shared with researchers who provide a methodologically sound proposal, to achieve aims in the approved proposal. To gain access, data requesters will need to sign a data access agreement
Clinical trial NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
Official title: Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select Population
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Change in practice patterns
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-11
Primary completion date: 2023-06-15
Completion date: 2023-06-15
Baseline population: The study closed early due to a change in practice patterns, and no participants were enrolled on arm A
Limitations and caveats: The study closed early due to change in practice patterns
Plan to share individual participant data: NO
Clinical trial NCT04629534: Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP) Pilot Study
Official title: Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP): Maternal Diet and Vitamin D Supplementation Effects on Preterm Infants, a Randomized Control Pilot Study.
Acronym: MoMO PIP
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: low enrollment, lack of funding
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-06
Primary completion date: 2021-12-31
Completion date: 2022-04-01
Baseline population: Mother/Infant Dyads that delivered at the Medical University of South Carolina between 24-34 weeks gestation were eligible for enrollment. Mother's and infants are counted separately in these results as 1 mother continued the study after her child was removed for parental preferences.
Limitations and caveats: Early termination leading to a small number of subjects analyzed with difficulty in enrollment. Technical issue with calculating total vitamin D intake through formula fortification and TPN along with the study drugs which can skew our data.
Plan to share individual participant data: NO
Clinical trial NCT03818542: A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
Official title: A Phase 1b Multi-Center Pharmacodynamic Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic considerations
Enrollment: 3.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-01-22
Primary completion date: 2020-09-23
Completion date: 2020-09-23
Plan to share individual participant data: NO
Clinical trial NCT04490018: Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents
Official title: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 463.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-16
Primary completion date: 2022-05-11
Completion date: 2022-05-11
Baseline population: Analysis was performed on all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03611582: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Official title: Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity
Acronym: STEP 3
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 611.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-01
Primary completion date: 2020-03-18
Completion date: 2020-04-28
Baseline population: Full analysis set (FAS) included all randomised participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT02716675: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Official title: A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 2699.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-04-06
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Baseline population: Safety Population
Clinical trial NCT04907227: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
Official title: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The data did not support study endpoints
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-23
Primary completion date: 2022-08-03
Completion date: 2023-07-18
Baseline population: The baseline analysis population consisted of all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03422536: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
Official title: A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 78.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-05
Primary completion date: 2022-03-29
Completion date: 2022-04-05
Clinical trial NCT04501796: A Trial of NT-I7 in COVID-19 (SPESELPIS)
Official title: A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19
Sponsor: NeoImmuneTech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was halted due to lack of patient population resulting in slow enrollment.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-27
Primary completion date: 2021-07-21
Completion date: 2023-02-23
Plan to share individual participant data: NO
Clinical trial NCT04294836: Curcumin in Advanced Cervical Cancer
Official title: Randomized Phase II Clinical Trial of Oral Turmeric Supplementation in Patients With Advanced Cervical Cancer
Sponsor: Instituto Nacional de Cancerologia, Columbia (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Issues with local regulatory authority
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2023-01-31
Completion date: 2023-12-31
Clinical trial NCT03970200: Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
Official title: A Phase II, Randomized Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Severe or Severe-Complicated/Fulminant Clostridium Difficile Infection
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative reasons.
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-16
Primary completion date: 2021-11-21
Completion date: 2022-05-14
Plan to share individual participant data: NO
Clinical trial NCT03403621: Hypertrophic Scar Prevention by Novel Topical Gel Application
Official title: Double Blind, Single-Center, Randomized, Within Subject Placebo, Phase I Study Evaluating the Effects of Novel Topical Gel in Prevention of Hypertrophic Scar Formation
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funding changes.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-05
Primary completion date: 2020-02-26
Completion date: 2020-02-26
Limitations and caveats: Terminated study due to funding changes.
Plan to share individual participant data: NO
Clinical trial NCT03871959: Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
Official title: CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma.
Acronym: CATRIPCA
Sponsor: Centre Leon Berard (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-15
Primary completion date: 2022-05-30
Completion date: 2022-06-08
Plan to share individual participant data: NO
Clinical trial NCT02943785: Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
Official title: Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1426.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-21
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Baseline population: Patient demographics were assessed in the Intent-to-Treat Analysis Set.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT05177328: Targeted Investigation of Microbiome Elimination
Official title: A Pilot Study to Evaluate the Survival of Transplanted Staphylococcus Hominis A9 on the Skin of Adults With Moderate-to-Severe Atopic Dermatitis (ADRN-UCSD-001)
Acronym: TIME-1
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Decision to terminate enrollment early was made by the protocol chair and NIAID
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-18
Primary completion date: 2023-10-13
Completion date: 2023-10-13
Clinical trial NCT03125187: Study With Heparin Sodium in Intravenous Administration
Official title: Phase I Study With Pharmacodynamic Determination of Unfractionated Heparin of Porcine Origin of the Company União Química of Intravenous Use in Healthy Participants
Sponsor: União Química Farmacêutica Nacional S/A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Delay in the R\&D stage
Enrollment: 24.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-02-20
Primary completion date: 2021-02-20
Completion date: 2022-11-10
Plan to share individual participant data: NO
Clinical trial NCT02826577: Effects of Pregnenolone on Perceived Social Isolation
Official title: Effects of Pregnenolone on Perceived Social Isolation: A Double-blind Randomized Electrical Neuroimaging Study
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Principal Investigator left institution.
Enrollment: 34.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-05-01
Primary completion date: 2021-12-21
Completion date: 2022-12-21
Baseline population: No data was collected or analyzed
Plan to share individual participant data: NO
Clinical trial NCT04542434: Niclosamide in COVID-19
Official title: A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19
Sponsor: Entero Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor asset acquired by another pharma company who opened their own IND for this compound. First Wave Bio never started this study in the US or ex-US.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-20
Primary completion date: 2022-01-20
Completion date: 2022-01-20
Clinical trial NCT04594941: A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes
Official title: A Descriptive, Comparative, Randomized, Crossover Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion Imaging Quality Using High Performance Liquid Chromatography (HPLC) and Solid Phase Extraction (SPE) Manufacturing Processes
Sponsor: GE Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-27
Primary completion date: 2022-05-26
Completion date: 2022-05-26
Clinical trial NCT03973697: Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
Official title: A Phase II, Randomized Trial to Evaluate the Optimal Dosing of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Recurrent Clostridium Difficile Infection
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative reasons
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-13
Primary completion date: 2021-08-11
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02332291: Connectivity Affecting the Antidepressant REsponse Study
Official title: Connectivity Affecting the Antidepressant REsponse (The CAARE Study)
Acronym: CAARE
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Baseline population: Participants randomized in 2:1 drug:placebo ratio.
Limitations and caveats: Single-site study; some missing data for self-report other outcome data
Clinical trial NCT03078855: A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Official title: ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
Acronym: ILyAD
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 211.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-07
Primary completion date: 2023-07-21
Completion date: 2024-07-02
Baseline population: The baseline analysis population included randomized and eligible participants that received at least one dose of vitamin D or placebo. Five enrolled participants were either ineligible or withdrew before receiving at least one dose of vitamin D or placebo and were excluded from the baseline analysis population.
Plan to share individual participant data: YES
IPD sharing description: De-identified data will be made available to researchers upon reasonable request.
IPD time frame: Data requests will be considered beginning in December 2024.
Clinical trial NCT03504501: Synaptic Plasticity and Cognitive Function in RASopathies
Official title: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders
Acronym: SynCoRAS
Sponsor: Technical University of Munich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study has been terminated prematurely due to recruitment difficulties. Current status: recruitment stopped and cleaning of the database is ongoing.
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-22
Primary completion date: 2023-02-09
Completion date: 2023-10-31
Plan to share individual participant data: NO
Clinical trial NCT03796676: JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Acronym: JADE TEEN
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 287.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-18
Primary completion date: 2020-04-08
Completion date: 2020-04-08
Baseline population: Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02117713: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Official title: A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Acronym: IMAGINE-II
Sponsor: Mirum Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-03-16
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Baseline population: In the lead-in Study LUM001-301, participants were randomized to receive either placebo or active drug (MRX). The last observation obtained before first dose of MRX (either for participants who received MRX or placebo LUM001-301) was used as the MRX baseline observation for all calculations of change. For participants who were assigned MRX in LUM001-301, results at each post-baseline analysis visit included up to 13 more weeks of treatment than participants who were assigned placebo.
Limitations and caveats: Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
Plan to share individual participant data: NO
Clinical trial NCT03857841: A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
Official title: A Safety Study of Intravenous Infusion of Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was discontinued due to a business decision; no safety concerns were noted.
Enrollment: 3.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-09
Primary completion date: 2021-05-20
Completion date: 2021-05-20
Baseline population: All subjects randomized and received clinical study material
Plan to share individual participant data: NO
Clinical trial NCT05703464: Elobixibat for Chronic Constipation Without Defecation Desire
Official title: A Multicenter, Single-group, Open-label, Before-and-after Study Confirming Recovery of Defecation Desire by Administration of Elobixibat in Patients With Chronic Constipation
Sponsor: International University of Health and Welfare (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Personal reason
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-09
Primary completion date: 2023-03-03
Completion date: 2023-03-03
Plan to share individual participant data: NO
Clinical trial NCT03557684: Leucine for Depression Study (L-DEP)
Official title: An Experimental Treatment Approach for Inflammation-Induced Depression
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: COVID-19
Enrollment: 59.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-09-01
Primary completion date: 2021-07-31
Completion date: 2021-07-31
Plan to share individual participant data: NO